[HTML][HTML] T790M and acquired resistance of EGFR TKI: a literature review of clinical reports
C Ma, S Wei, Y Song - Journal of thoracic disease, 2011 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C Rolfo, E Giovannetti, DS Hong, T Bivona… - Cancer treatment …, 2014 - Elsevier
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
[HTML][HTML] Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy
K Domvri, P Zarogoulidis, K Darwiche… - Journal of …, 2013 - ncbi.nlm.nih.gov
Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …
[HTML][HTML] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
Lung cancer in never smokers
P Yang - Seminars in respiratory and critical care medicine, 2011 - thieme-connect.com
Lung cancer in never smokers (LCINS) has lately been recognized as a unique disease
based on rapidly gained knowledge from genomic changes to treatment responses. The …
based on rapidly gained knowledge from genomic changes to treatment responses. The …
[HTML][HTML] Efficacy and safety of gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line …
Y Song, YL Wu, LJ Cao, JH Chen, ZY Ma… - American Journal of …, 2019 - journals.lww.com
Objective: There is no standard care for advanced non–small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway
Q Luo, Y Gu, W Zheng, X Wu, F Gong, L Gu… - Toxicology and applied …, 2011 - Elsevier
Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has
been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong …
been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong …
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
F Conforti, C Catania, F Toffalorio, M Duca, G Spitaleri… - Lung Cancer, 2013 - Elsevier
Introduction Recent data show that EGFR pathway and its inhibition maintain their role after
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …
Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular …
A Pallis, E Briasoulis, H Linardou… - Current medicinal …, 2011 - ingentaconnect.com
Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth
factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors …
factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine kinase inhibitors …